Siponimod for Alzheimer's Disease

Migration, Crosslink

📖

Siponimod for Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-siponimod-alzheimers-d

📖 Wiki Page

therapeutic1219 wordssynced 2026-04-02

Siponimod for Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Siponimod for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">S1P targets</td>
<td>S1P1, S1P5 (selective)</td>
</tr>
<tr>
<td class="label">Cardiac effects</td>
<td>Low (S1P3 sparing)</td>
</tr>
<tr>
<td class="label">FDA approval</td>
<td>MS (2019), CIS</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">AD trials</td>
<td>NCT06639282 (active)</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Location</td>
</tr>
<tr>
<td class="label">S1P1R</td>
<td>Lymphocytes, neurons, glia</td>
</tr>
<tr>
<td class="label">S1P2R</td>
<td>CNS neurons, astrocytes</td>
</tr>
<tr>
<td class="label">S1P3R</td>
<td>Heart, immune cells</td>
</tr>
<tr>
<td class="label">S1P4R</td>
<td>Immune cells, lymphoid</td>
</tr>
<tr>
<td class="label">S1P5R</td>
<td>CNS neurons, oligodendrocytes</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Liver enzyme elevation</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Bradycardia (first dose)</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Hypertension</td>
<td>8-12%</td>
</tr>
<tr>
<td class="label">Lymphopenia</td>
<td

...

Siponimod for Alzheimer's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Siponimod for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">S1P targets</td>
<td>S1P1, S1P5 (selective)</td>
</tr>
<tr>
<td class="label">Cardiac effects</td>
<td>Low (S1P3 sparing)</td>
</tr>
<tr>
<td class="label">FDA approval</td>
<td>MS (2019), CIS</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Good</td>
</tr>
<tr>
<td class="label">AD trials</td>
<td>NCT06639282 (active)</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Location</td>
</tr>
<tr>
<td class="label">S1P1R</td>
<td>Lymphocytes, neurons, glia</td>
</tr>
<tr>
<td class="label">S1P2R</td>
<td>CNS neurons, astrocytes</td>
</tr>
<tr>
<td class="label">S1P3R</td>
<td>Heart, immune cells</td>
</tr>
<tr>
<td class="label">S1P4R</td>
<td>Immune cells, lymphoid</td>
</tr>
<tr>
<td class="label">S1P5R</td>
<td>CNS neurons, oligodendrocytes</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Liver enzyme elevation</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Bradycardia (first dose)</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Hypertension</td>
<td>8-12%</td>
</tr>
<tr>
<td class="label">Lymphopenia</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Respiratory infection</td>
<td>5-8%</td>
</tr>
<tr>
<td class="label">Dizziness</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">S1P targets</td>
<td>S1P1, S1P5 (selective)</td>
</tr>
<tr>
<td class="label">Cardiac effects</td>
<td>Low (S1P3 sparing)</td>
</tr>
<tr>
<td class="label">First-dose observation</td>
<td>Required</td>
</tr>
<tr>
<td class="label">FDA approval</td>
<td>MS (2019), CIS</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">AD trials</td>
<td>NCT06639282</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Titration over 6 days</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Repurposing advantage</td>
<td>Known safety profile from MS indication (60,000+ patients treated)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Addresses both neuroinflammation (immune) and direct neuroprotection</td>
</tr>
<tr>
<td class="label">Synergy potential</td>
<td>Could combine with anti-amyloid antibodies (lecanemab, donanemab) for complementary pathways</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Excellent (lipophilic small molecule, active CNS uptake)</td>
</tr>
<tr>
<td class="label">Selectivity advantage</td>
<td>S1P3 sparing reduces cardiac toxicity vs fingolimod</td>
</tr>
<tr>
<td class="label">Limitations</td>
<td>Requires cardiac monitoring; lymphocyte reduction may increase infection risk; long-term AD data pending</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

Siponimod (brand name Mayzent, Novartis) is a selective sphingosine-1-phosphate (S1P) receptor modulator already approved for multiple sclerosis (MS). It is now being repositioned for [Alzheimer's disease](/diseases/alzheimers-disease) based on compelling preclinical evidence showing neuroprotective and anti-inflammatory effects. A Phase II clinical trial (NCT06639282) is currently recruiting to evaluate the efficacy of siponimod in AD patients["@brock2022"][@selkoe2021].

Siponimod binds to S1P receptor subtypes 1 and 5 (S1P1R, S1P5R), modulating lymphocyte trafficking and exerting direct neuroprotective effects in the CNS. Unlike fingolimod (non-selective S1P modulator), siponimod's selectivity reduces cardiac side effects while maintaining therapeutic benefit.

Mechanism of Action

S1P Receptor Modulation

Siponimod acts as a functional antagonist at S1P1R and agonist at S1P5R:

S1P1R (lymphocytes): Internalization and degradation → reduced lymphocyte egress from lymph nodes → fewer pro-inflammatory T cells entering the CNS
S1P5R (CNS): Direct neuroprotective signaling in oligodendrocytes, astrocytes, and neurons

Neuroprotective Effects in AD

Siponimod provides benefit through multiple mechanisms[@paris2019]:

Aβ-induced neurotoxicity: S1P5R activation protects neurons from amyloid-β oligomer toxicity
Microglial modulation: Shifts microglia toward the protective M2 phenotype
Tau phosphorylation: S1P signaling reduces GSK-3β activity, lowering tau phosphorylation
Synaptic protection: Inhibits complement-mediated synaptic pruning
Blood-brain barrier: Reduces BBB leakiness, limiting peripheral immune cell entry

Clinical Trial Details

NCT06639282 — Repurposing Siponimod for Alzheimer's Disease:

Design: Randomized, double-blind, placebo-controlled Phase II
Population: Patients with early-to-moderate AD (MMSE 16-26)
Intervention: Siponimod oral capsules (dose-titrated to target dose)
Primary outcomes: Change in ADAS-Cog13 score at 12 months
Secondary outcomes: CSF biomarkers (p-tau181, Aβ42), brain MRI (hippocampal volume), CDR-SB
Status: RECRUITING

Preclinical Evidence

Key findings supporting siponimod in AD[@brock2022][@paris2019]:

APP/PS1 mice: Siponimod treatment reduced amyloid plaque load by ~30%, improved spatial memory (Morris water maze), and preserved synaptic density
3xTg-AD mice: Reduced tau phosphorylation and improved cognitive performance
Human data: S1P receptor expression is altered in AD brain tissue; S1P levels are reduced in CSF from AD patients

Comparison with Fingolimod

S1P Receptor Biology and Neuroprotection

Sphingosine-1-phosphate (S1P) is a bioactive lipid signaling molecule that regulates diverse cellular processes through five G protein-coupled receptor subtypes (S1P1R-S1P5R)[@oukolov2020]. In the CNS, S1P signaling is involved in:

Neuronal survival: S1P5R activation promotes pro-survival signaling via PI3K/Akt and MAPK/ERK pathways
Oligodendrocyte function: S1P1R and S1P5R regulate oligodendrocyte precursor cell migration, differentiation, and myelination
Astrocyte reactivity: S1P signaling modulates astrocyte inflammatory responses
Microglial polarization: S1P receptors influence microglial phenotype switching between M1 (pro-inflammatory) and M2 (protective)

S1P Receptor Subtype Distribution

Neuroprotective Mechanisms in AD

Siponimod provides multi-modal neuroprotection through the following pathways[@paris2019][@selkoe2021]:

Modulation of Aβ-induced toxicity: S1P5R activation in hippocampal and cortical neurons upregulates BDNF expression and activates TrkB signaling, conferring resistance to amyloid-β oligomer toxicity. Preclinical studies in APP/PS1 mice showed 30% reduction in amyloid plaque burden with siponimod treatment.

Microglial phenotype shift: Siponimod promotes switching from M1 (CD16/32+, IL-1β+, TNF-α+) to M2 (CD206+, Arg1+, IL-10+) phenotype via S1P1R on microglia. This reduces pro-inflammatory cytokine release and enhances phagocytic clearance of Aβ deposits.

Tau phosphorylation reduction: S1P signaling via S1P5R inhibits GSK-3β activity through PP2A activation, reducing tau phosphorylation at AD-relevant epitopes (Ser396, Thr231). This may limit NFT formation.

Synaptic protection: Siponimod inhibits complement C1q-mediated synaptic pruning by reducing microglial C1q expression. This preserves glutamatergic synapse density, which is critical for memory function.

Blood-brain barrier repair: S1P1R activation on endothelial cells promotes BBB integrity by stabilizing VE-cadherin junctions and reducing matrix metalloproteinase-9 (MMP-9) activity, limiting peripheral immune cell infiltration.

Lipid raft modulation: S1P receptors localize to membrane lipid rafts where they regulate APP processing. Siponimod reduces BACE1 activity through raft modulation, lowering Aβ generation.

Pharmacokinetics

Absorption: Rapid oral absorption, Tmax ~4 hours
Bioavailability: ~87% (food has minimal effect)
Distribution: High tissue penetration, including CNS (brain-to-plasma ratio ~10:1)
Metabolism: Hepatic (CYP2C9, CYP3A4), producing active metabolites
Half-life: ~30 hours (effective half-life enabling once-daily dosing)
Elimination: Fecal and renal
Drug interactions: CYP2C9/CYP3A4 inhibitors increase exposure; CYP3A4 inducers decrease exposure

Safety and Monitoring

Contraindications

Cardiovascular: Sick sinus syndrome, second/third-degree AV block without pacemaker, QTc > 500ms
Hepatic: Severe hepatic impairment
Pregnancy: Category D; effective contraception required during and 10 days after treatment

Common Adverse Effects

Required Monitoring Protocol

First-dose observation: 6-hour monitoring with ECG for cardiac patients

Baseline labs: CBC, LFTs, lipid panel

Monthly: LFTs for first 3 months, then every 3 months

Every 6 months: CBC, lipid panel

Annual: Ophthalmologic exam (macular edema risk)

Comparison with Other S1P Modulators

Therapeutic Potential

Cross-Linking

[Alzheimer's Disease](/diseases/alzheimers-disease)
[S1P Signaling](/mechanisms/sphingosine-1-phosphate-signaling)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

External Links

[ClinicalTrials.gov: NCT06639282](https://clinicaltrials.gov/study/NCT06639282)
[Mayzent (Novartis) prescribing information](https://www.novartis.com/us-en/)
[PubMed: Siponimod AD research](https://pubmed.ncbi.nlm.nih.gov/?term=siponimod+alzheimer)

📖 View canonical wiki page →

Related Entities

therapeutics-siponimod-alzheimers-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-siponimod-alzheimers-disease
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-90ff22857488
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-siponimod-alzheimers-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

211

Outgoing

224

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Siponimod for Alzheimer's Disease

Siponimod for Alzheimer's Disease

Siponimod for Alzheimer's Disease

Overview

Mechanism of Action

S1P Receptor Modulation

Neuroprotective Effects in AD

Clinical Trial Details

Preclinical Evidence

Comparison with Fingolimod

S1P Receptor Biology and Neuroprotection

S1P Receptor Subtype Distribution

Neuroprotective Mechanisms in AD

Pharmacokinetics

Safety and Monitoring

Contraindications

Common Adverse Effects

Required Monitoring Protocol

Comparison with Other S1P Modulators

Therapeutic Potential

Cross-Linking

External Links

💬 Discussion